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Abstract
Introduction: Prognostic stratification of cardiac arrest survivors is essential for the selection of the most
appropriate therapeutic strategy. However, accurate early outcome predictions for this patient population remain
challenging. At present, there is a lack of data examining the prognostic value of C-terminal provasopressin
(copeptin) in cardiac arrest survivors.
Methods: A group of 40 out-of-hospital cardiac arrest survivors who were treated with endovascular hypothermia
was analyzed. Copeptin levels were measured in blood samples taken at admission using a commercially available
immunoassay. Neurological outcome was assessed at 30 days post admission according to the Cerebral
Performance Category (CPC): CPC 1, no neurological deficit; CPC 2, mild to moderate dysfunction; CPC 3, severe
dysfunction; CPC 4, coma; and CPC 5, death.
Results: Copeptin levels were significantly lower in patients with CPC 1 compared with CPC 2 or CPC 3 to CPC 5
(74.3 ± 14.4 pmol/l, 219.8 ± 33.9 pmol/l and 302.7 ± 52.1 pmol/l, respectively; P < 0.0001). Using an optimal cutoff
value ≤ 217.9 pmol/l calculated from the receiver operating characteristic curve (area under curve = 0.801, 95%
confidence interval = 0.644 to 0.910; P = 0.0001), the sensitivity of predicting survival with good neurological
outcome was 78.6% and the specificity was 75.0%. Multiple logistic regression analysis revealed that a copeptin
level > 217.9 pmol/l was an independent predictor of severe neurological dysfunction or death, with an adjusted
odds ratio of 27.00 (95% confidence interval = 2.27 to 321.68; P = 0.009).
Conclusion: The present study found that copeptin levels have a significant prognostic value at the time of
hospital admission, and are a promising diagnostic tool for predicting outcomes in out-of-hospital cardiac arrest
survivors.
Introduction
A large number of patients experience cardiac arrest each
year, which is associated with high mortality and poor
neurological outcomes [1,2]. In patients who survived to
hospital admission, brain injury was the major cause of
death; ischemic brain damage is responsible for approxi-
mately 70% of in-hospital deaths after out-of-hospital
cardiac arrest [1,2]. Cerebral ischemia during cardiac
arrest is also responsible for significant encephalopathy
in many cardiac arrest survivors [1,2]. Before the intro-
duction of therapeutic hypothermia into clinical practice,
only 26 to 39% of patients survived cardiac arrest with
good neurological outcomes - and even with all of the
current therapeutic options, the proportion of cardiac
arrest survivors with good neurological outcome remains
as low as 49 to 55% [3,4]. Early risk stratification and out-
come prediction are therefore essential for appropriate
management modification and tailored resource
allocation.
Several diagnostic tools have recently been shown to
have prognostic value for cardiac arrest survivors who
are treated according to contemporary recommendations,
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which include therapeutic hypothermia. Poor outcomes
after cardiac arrest can be predicted by increased serum
levels of neuron-specific enolase or protein S-100B, gen-
eralized background suppression or epileptiform com-
plexes on electroencephalography, bilaterally absent
cortical responses on somatosensory evoked potentials,
and diffuse brain edema on computed tomography or
magnetic resonance imaging [5]. To date, however, a
reproducible and universally recognized prognostication
method with a minimal false-positive rate is still not
available for cardiac arrest patients.
Copeptin is the C-terminal fragment of the provasopre-
sin peptide, and it is co-released from the hypothalamus,
in an equimolar ratio, with the hypothalamic stress
hormone vasopressin. Recently, it was shown that copep-
tin levels predict outcomes in several medical conditions,
such as acute exacerbation of chronic obstructive pul-
monary disease [6], ischemic stroke [7], myocardial
infarction [8] and heart failure [9,10]. Data on the prog-
nostic value of copeptin in cardiac arrest survivors are,
however, still lacking. The objective of the present study
was therefore to assess the utility of copeptin levels mea-
sured at admission in predicting outcome for out-of-
hospital cardiac arrest survivors treated with endovascu-
lar hypothermia.
Materials and methods
The present study was performed in accordance with the
Declaration of Helsinki and the study protocol was
approved by the Institutional Ethics Committee of the
Na Homolce Hospital (Prague, Czech Republic). Surviv-
ing patients with favorable neurological outcomes and
family members of deceased subjects or subjects with
unfavorable neurological outcomes provided written
informed consent retrospectively. Blood samples drawn
from patients who were not willing to participate in the
trial (which was expressed by family members in cases
involving deceased subjects or subjects with unfavorable
neurological outcomes) were discarded and the clinical
data were not used in the analysis.
Patients who experienced cardiac arrest out of hospital
with indications for mild therapeutic hypothermia (per-
sistent coma with Glasgow Coma Score ≤ 8) were eligi-
ble to participate in the present study. Induction of
hypothermia was initiated in the ambulance before hos-
pital admission by infusion of ice-cold saline at a rate of
30 ml/kg/hour. Infusion continued after admission and
was discontinued when the core temperature reached
34°C. An endovascular cooling method (Thermogard
XP; Zoll, Chelmsford, MA, USA) with a target tempera-
ture of 33°C and a 24-hour hypothermia protocol was
used in all patients [11]. Patients with ST-elevation
myocardial infarction underwent direct percutaneous
coronary intervention.
Blood samples for the measurement of copeptin levels
were drawn at admission to the hospital (ICU or catheteri-
zation laboratory) before any interventional procedure.
The serum was immediately separated by centrifugation at
1,500 rpm for 5 minutes and aliquots were stored at -70°C
until measurement. Copeptin serum concentrations were
assessed with the commercially available BRAHMS copep-
tin kryptor assay according to the manufacturer’s instruc-
tions (BRAHMS, Hennigsdorf, Germany). The detection
limit of the assay was 4.8 pmol/l, and the functional assay
sensitivity was < 12 pmol/l. Lactate levels were measured
routinely at hospital admission using a RAPIDPoint 500
analyzer (Siemens, Munich, Germany). Investigators per-
forming the laboratory analyses were blinded to the clini-
cal results.
Neurological outcome was assessed according to Cere-
bral Performance Category (CPC) [12] at 30 days post
admission, which is widely used in research and quality
assurance to assess neurological outcome following car-
diac arrest: CPC 1, no neurological deficit; CPC 2, mild
to moderate dysfunction; CPC 3, severe dysfunction;
CPC 4, coma; and CPC 5, death. Physicians performing
the CPC assessment were blinded to the copeptin levels.
The time to return of spontaneous circulation was
defined as a period of time from collapse (obtained
from witness) to restoration of spontaneous perfusing
rhythm.
Statistical methods
Continuous variables are presented as the mean ± stan-
dard deviation and compared using an unpaired t test and
one-way analysis of variance with the Newman-Keuls mul-
tiple comparisons post test; categorical variables were pre-
sented as percentages and compared with Fisher’s exact
test. Receiver operating characteristic (ROC) curves were
constructed to determine the optimal sensitivity and speci-
ficity of copeptin levels for predicting outcomes. A multi-
ple logistic regression analysis model was applied to
evaluate independent predictors of poor neurological out-
come or death, and the prognostic value of copeptin levels.
P < 0.05 was considered statistically significant. Statistical
analyses were performed using GraphPad Prism version 5
(GraphPad Software, La Jolla, CA, USA) and MedCalc ver-
sion 12 (MedCalc, Mariakerke, Belgium).
Results
Forty-six patients were eligible to participate in the pre-
sent study during the enrollment period (June 2010 to
December 2011). One patient was excluded due to tech-
nical problems with blood-sample handling and five
patients were excluded because written informed consent
could not be obtained. In total, 40 patients (mean age 58
years) were included in the study, the majority of whom
(32 of 40) were male (Table 1). Nineteen patients in the
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group survived without neurological dysfunction
(CPC 1); nine patients survived with mild-to-moderate
dysfunction (CPC 2); three survivors experienced severe
neurological dysfunction (CPC 3 to 4); and nine patients
died (CPC 5).
Copeptin levels were significantly lower in patients
with CPC 1 compared with CPC 2 or CPC 3 to CPC 5
(74.3 ± 65.6 pmol/l, 219.8 ± 101.7 pmol/l and 302.7 ±
180.5 pmol/l, respectively; P < 0.0001) (Figure 1). The
ROC curve was used to estimate the optimal cutoff level
of copeptin for good neurological outcomes (CPC 1 and
CPC 2; area under curve = 0.801, 95% confidence inter-
val = 0.644 to 0.910; P = 0.0001) (Figure 2). Using an
optimal cutoff value ≤ 217.9 pmol/l calculated from the
ROC curve, the sensitivity of predicting survival with
good neurological outcome was 78.6% and the specifi-
city was 75.0% (Figure 2). Multiple logistic regression
analysis was applied to determine whether the copeptin
level was an independent predictor for poor neurological
outcome or death. In the analysis, a copeptin level >
217.9 pmol/l was found to be an independent predictor,
with an adjusted odds ratio of 27.00 (95% confidence
interval = 2.27 to 321.68; P = 0.009) (Table 2).
Discussion
The major finding of the present study was that the
copeptin level, assessed at hospital admission, can predict
neurological outcomes in cardiac arrest survivors.
Table 1 Baseline characteristics
CPC 1 to 2 (n = 28) CPC 3 to 5 (n = 12) P value Odds ratio 95% CI
Age (years) 64.4 ± 12.4 69.3 ± 13.7 0.30 -14 to 4.5
Gender, male (%) 85.7 66.7 1.00 1.00 0.2 to 6.0
Diabetes (%) 46.4 41.7 1.00 1.21 0.3 to 4.8
Hypertension (%) 78.3 66.6 0.45 1.81 0.4 to 8.2
VFib (%) 71.4 75.0 1.00 0.83 0.2 to 3.9
Asystole (%) 21.4 25.0 1.00 0.82 0.2 to 4.0
AMI (%) 50.0 58.3 0.74 0.71 0.2 to 2.8
ROSC (min) 16.64 ± 9.34 22.82 ± 11.44 0.12 -14 to 1.7
LVEF (%) 35.87 ± 12.67 30.00 ± 15.67 0.26 -4.6 to 16
Lactatea (mmol/l) 5.08 ± 3.19 8.25 ± 4.10 0.08 -6.7 to 0.4
Values expressed as the mean ± standard deviation unless otherwise indicated. aLactate level at admission. AMI, acute myocardial infarction; CI, confidence
interval; CPC, Cerebral Performance Category; LVEF, left ventricular ejection fraction within 2 hours of admission; ROSC, return of spontaneous circulation; VFib,
ventricular fibrillation.
Figure 1 Copeptin levels at hospital admission in cardiac arrest
survivors according to Cerebral Performance Category. Data
presented as mean ± standard deviation. CPC, Cerebral Performance
Category.
Figure 2 Receiver-operating characteristic curve of copeptin
for predicting outcomes in cardiac arrest survivors. The optimal
cutoff value for good neurological outcome (Cerebral Performance
Categories 1 and 2) calculated from this receiver operating
characteristic curve was ≤ 217.9 pmol/l, with sensitivity 78.6% and
specificity 75.0%. Dotted lines: 95% confidence interval (CI) bounds.
AUC, area under curve.
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A cutoff value ≤ 217.9 pmol/l was determined by ROC
curve analysis; patients with a copeptin level < 217.9
pmol/l were more likely to survive to 30 days without sig-
nificant neurological dysfunction compared with patients
with a copeptin level > 217.9 pmol/l. Early outcome pre-
diction is challenging in cardiac arrest survivors, and the
optimal timing as well as the methods used for prognosti-
cation remain controversial. Several approaches have
been shown to have a prognostic value several days after
cardiac arrest, such as assessment of serum markers of
brain injury (neuron-specific enolase, S-100B), electroen-
cephalography, somatosensory evoked potentials, and
neuroimaging [5]. At the present time, however, only a
very limited number of parameters can be used for prog-
nosis prediction at the time of hospital admission after
cardiac arrest. In this respect, including the measurement
of copeptin levels among the screening laboratory inves-
tigations in these patients, using a widely available
commercial assay may offer a relatively simple prognosti-
cation method.
The results of the present study are in agreement with
other studies describing the prognostic value of copeptin
levels in several other acute and/or critical conditions
[13]. Copeptin levels have been recently shown to corre-
late with outcomes in the following conditions: acute
exacerbation of chronic obstructive pulmonary disease
[6], ischemic stroke [7], myocardial infarction [8,14],
heart failure [9,10], and even in patients presenting to the
emergency department with nonspecific complaints [15].
Moreover, Jarai and colleagues reported that preoperative
copeptin concentrations predict postoperative outcome
after major vascular surgery [16]. Our observations are
also in good agreement with the study by Kim and collea-
gues, in which they described that cardiac arrest survivors
with relative adrenal insufficiency, higher blood levels of
adrenocorticotropic hormone and vasopressin have poor
outcomes [17].
The present study, however, has several limitations
mostly attributable to its limited sample size. Furthermore,
all of the patients in our group were out-of-hospital car-
diac arrest survivors who were treated with mild endovas-
cular hypothermia, and it remains uncertain whether our
results can be generalized to all cardiac arrest survivors,
including patients who experience in-hospital arrest and
those undergoing different cooling methods. Another
possible limitation is that patients with chronic diseases
that are known to be associated with elevation of copeptin
such as heart or renal failure were not excluded.
Conclusion
Our results demonstrate that copeptin level assessment
at the time of hospital admission in cardiac arrest survi-
vors can be useful in the prediction of neurological out-
comes and mortality. Currently, a universal strategy for
risk stratification after out-of-hospital cardiac arrest is
still under development, and the use of copeptin mea-
surement at admission may contribute significantly to
improving both the speed and the accuracy of outcome
prediction for this patient population.
Key messages
• Copeptin level at admission predicts outcomes in
out-of-hospital cardiac arrest survivors.
• Patients with a copeptin level < 217.9 pmol/l were
more likely to survive to 30 days without significant
neurological dysfunction.
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